EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice

Cinzia Pellegrini, Beatrice Casadei, Alessandro Broccoli, Martina Cantelli, Gabriele Gugliotta, Marianna Gentilini, Matteo Carella, Vittorio Stefoni, Nicole Fabbri, Giulia Gabrielli, Lisa Argnani, Camilla Mazzoni und 3 weitere

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06255-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Cinzia Pellegrini und 14 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Via Massarenti, 9, Bologna, 40138, Italy. Hauptthemen laut MEDLINE: Hodgkin Disease, Salvage Therapy, Immune Checkpoint Inhibitors, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alma Mater Studiorum - Università di Bologna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (CPIs) emerged as an effective and safe therapeutic option for patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, many patients lose their response to CPIs. To improve outcomes in this setting, two strategies can be considered: salvage chemotherapy (CHT) for those with an unsatisfactory response, and autologous stem-cell transplantation (auto-SCT) as a consolidation for patients with at least partial response (PR). We analyzed retrospectively the effectiveness in terms of rate of response and survivals of these two approaches in cohort 1 (salvage CHT) and in cohort 2 (auto-SCT consolidation). Adverse events were also assessed. A total of 45 heavily pre-treated patients were analyzed (median of 4 prior therapies; 93.3% refractory to the last therapy). Thirty patients received further CHT at a median of 32 days (range 1-1213) after CPI Fifteen patients in cohort 2 underwent auto-SCT, with 8 in complete response (CR) and 7 in PR. In cohort 1 a final overall response rate (ORR) of 50.0% with a median progression-free survival of 24.6 months. In cohort 2, the ORR was 93.3% (all CR) with median survivals not reached. No unexpected or cumulative toxicities were observed. Our findings suggest that auto-SCT is an effective consolidation strategy for cHL patients who achieve at least a PR after CPI therapy, despite multiple prior lines of treatment. Additionally, CPIs treatment appears to sensitize heavily pre-treated and chemorefractory patients to subsequent chemotherapy, potentially facilitating successful transplant consolidation and improving the chances of cure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseSalvage TherapyImmune Checkpoint InhibitorsHematopoietic Stem Cell TransplantationHumansMaleFemaleAdultMiddle AgedRetrospective StudiesYoung AdultAdolescentAgedTransplantation, AutologousRecurrence

Stichwörter der Autor:innen

Checkpoint inhibitorsConsolidationReal-worldRelapsed/refractory Hodgkin lymphomaSalvage treatments

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Via Massarenti, 9, Bologna, 40138, Italy.
  • Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Via Massarenti, 9, Bologna, 40138, Italy. pierluigi.zinzani@unibo.it.
  • Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy. pierluigi.zinzani@unibo.it.

Förderung

  • Alma Mater Studiorum - Università di Bologna

Zitieren

APA

Pellegrini, C., Casadei, B., Broccoli, A., Cantelli, M., Gugliotta, G., Gentilini, M., Carella, M., Stefoni, V., Fabbri, N., Gabrielli, G., Argnani, L., Mazzoni, C., Maglio, P., Bagnato, G., & Zinzani, P. L. (2025). Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice. Annals of Hematology. https://doi.org/10.1007/s00277-025-06255-8

Vancouver

Pellegrini C, Casadei B, Broccoli A, Cantelli M, Gugliotta G, Gentilini M, et al. Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice. Annals of Hematology. 2025. doi:10.1007/s00277-025-06255-8

BibTeX
@article{Pellegrini2025,
  author = {Pellegrini, Cinzia and Casadei, Beatrice and Broccoli, Alessandro and Cantelli, Martina and Gugliotta, Gabriele and Gentilini, Marianna and Carella, Matteo and Stefoni, Vittorio and Fabbri, Nicole and Gabrielli, Giulia and Argnani, Lisa and Mazzoni, Camilla and Maglio, Pierluca and Bagnato, Gianmarco and Zinzani, Pier Luigi},
  title = {Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06255-8}
}
Kostenlos starten →